Displaying drugs 6826 - 6850 of 8033 in total
Deracoxib
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Description: … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to ... Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation …
Anti-SARS-CoV-2 IgY
Anti-SARS-CoV-2 IgY are chicken egg antibodies to SARS-CoV-2 which have the potential to provide temporary protection against the virus when administered as intranasal drops. To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune...
Investigational
Matched Description: … antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of ... From there, the chicken antibodies are harvested from the egg yolks of the eggs laid by these chickens ... investigated against COVID-19 in the trial NCT04567810 (Safety, Tolerability, and Pharmacokinetics of …
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
Experimental
Matched Description: … 9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour …
Peptide YY (3-36)
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …
PM02734
PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
Investigational
Matched Description: … PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types …
Caprospinol
Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
Investigational
Matched Description: … Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from …
NAV 1800
RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
Investigational
Matched Description: … tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of …
Ropidoxuridine
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Investigational
Matched Description: … IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of …
Ponazuril
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Matched Description: … the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of …
Berzosertib
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Investigational
Matched Description: … Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous …
Sonolisib
Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.
Investigational
Matched Description: … Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid …
CEP-9722
CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).
Investigational
Matched Description: … CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With …
Fitusiran
Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B).
Investigational
Matched Description: … Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational …
PF-06291874
PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of …
Esaxerenone
Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).
Investigational
Matched Description: … Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy …
2'-Fucosyllactose
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … 2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of …
Dirocaftor
Dirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).
Investigational
Matched Description: … investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of …
G305
G305 is a recombinant NY-ESO-1 protein plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with LV305.
Investigational
Matched Description: … G305 is an active component of CMB305 along with [LV305].[L47346] …
AMP-201
AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Investigational
Matched Description: … It is under investigation for the treatment of collagen Q congenital myasthenia. …
4-Hydroxytestosterone
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts...
Experimental
Illicit
Matched Description: … of the many byproducts of formestane metabolism. ... Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one …
NNZ-2591
NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and...
Investigational
Matched Description: … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic ... glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been ... [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of …
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate ... The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. ... Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox …
RUTI® Vaccine
The RUTI® Vaccine contains fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli. The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response against tuberculosis. Much like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. Sponsored by Fundació Institut...
Investigational
Matched Description: … The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response ... Sponsored by Fundació Institut Germans Trias i Pujol, the RUTI® Vaccine is being tested for prevention of …
RH-1
RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.
Experimental
Investigational
Matched Description: … RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma …
GlycoPEG-GCSF
GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Investigational
Matched Description: … GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of …
Displaying drugs 6826 - 6850 of 8033 in total